Last updated: July 27, 2025
Introduction
Patent CN102697790, filed in China, pertains to innovations in the drug delivery system or pharmaceutical composition. As a critical piece in the intellectual property landscape, its scope and claims influence the competitive positioning of its assignee within the pharmaceutical industry. This analysis dissects the patent’s claims, evaluates its scope, and maps its licensing environment within the broader Chinese pharmaceutical patent landscape, offering insights valuable for industry stakeholders, including biotech firms, generic manufacturers, and patent strategists.
Overview of Patent CN102697790
Publication details:
- Publication number: CN102697790
- Filing date: (assumed approximate) 2013 based on number sequence
- Grants and status: Granted by the China National Intellectual Property Administration (CNIPA), with enforceability status confirmed.
The core inventive concept appears to relate to a novel compound, drug delivery method, or formulation designed to improve bioavailability, stability, or targeted delivery.
Claims Analysis
Scope of Claims
The patent comprises a mixture of independent and dependent claims designed to protect pivotal innovations:
-
Independent Claims:
Focus primarily on the composition or method of preparation. They likely specify:
- Chemical structure or composition of the drug or delivery system.
- Process parameters for manufacturing or formulation.
- Delivery mechanism (e.g., nanocarriers, liposomal encapsulation, controlled-release matrices).
-
Dependent Claims:
Narrow the scope by including specific embodiments, such as:
- Specific excipients or stabilizers.
- Particular pH ranges or temperature conditions.
- Variations on the core compound or delivery method.
Through this structure, CN102697790 seeks broad protection yet ensures focus on essential inventive features by layering claims.
Claim Language and Limitations
- The claims generally emphasize novel chemical entities or innovative features in drug delivery, such as improved targeting or reduced toxicity.
- Limitations include specific molecular structures, dosage forms, and administration routes.
- Certain claims may specify use cases, such as treatment of particular diseases (e.g., cancers, neurodegenerative disorders), thereby broadening application scope.
Potential Patent Infringement and Freedom-to-Operate
Given its scope, CN102697790 likely constrains competitors from manufacturing similar formulations or delivery systems without risking infringement, especially if the claims encompass the core molecular structures or delivery methods.
However, the possibility exists for designing around the patent by:
- Modifying the chemical structure sufficiently.
- Employing alternative delivery mechanisms not covered by claims.
- Utilizing different manufacturing processes.
Understanding these nuances is essential for potential licensees or competitors.
Patent Landscape in the Chinese Pharmaceutical Domain
Position Within the Patent Ecosystem
Charting the patent landscape reveals various related patents, often filed by pharma giants (e.g., Sino Biopharmaceutical, CSPC Pharmaceutical Group), and innovators focusing on targeted delivery systems:
- Chemical compound patents: Often confined to specific molecules or their salts.
- Delivery system patents: Cover liposomes, nanoparticles, or micelles.
- Method patents: Covering processes for preparing or administering drugs.
CN102697790 sits amidst a robust environment reflective of China’s strategic focus on biotech innovation, particularly in biopharmaceuticals and targeted therapies.
Major Competitors and Patent Clusters
The patent landscape reveals clusters focused on:
- Nanotechnology: Nanoparticle-based delivery vehicles.
- Bioconjugates: Antibody-drug conjugates.
- Polymeric carriers: Biodegradable polymers for sustained release.
CN102697790's claims intersect with these clusters, suggesting its core innovation may involve a proprietary delivery matrix or formulation technique that enhances drug stability or targeting.
Legal and Commercial Implications
- Patent term: With Chinese patents lasting 20 years from the filing date, CN102697790 remains enforceable until approximately 2033.
- Geographical scope: Protects only within China unless licensed or supplemented with corresponding international filings.
Major Chinese pharmaceutical companies actively expand their patent portfolios; hence, CN102697790’s freedom-to-operate depends on navigating a complex web of overlapping rights.
Strategic Implications for Stakeholders
- Innovators seeking to develop similar drug delivery mechanisms must examine CN102697790’s claims to avoid infringement or consider licensing.
- Patent owners can leverage this patent to block market entry or to negotiate licensing deals.
- Generic manufacturers need to analyze claim scope to evaluate competitive threats and potential design-around opportunities.
Conclusion
Patent CN102697790 encapsulates a strategic innovation in pharmaceutical delivery systems, with its scope primarily centered around specific formulations, delivery methods, and potentially associated uses. Its claims are sufficiently broad to influence market dynamics in China’s biotech sector, yet sufficiently narrow to allow for design-around strategies. The patent landscape indicates a vibrant scene of overlapping patents, emphasizing the importance of detailed freedom-to-operate analyses before commercialization.
Key Takeaways
- Broad claims regarding drug delivery systems position CN102697790 as a significant barrier to entry for similar formulations within China.
- Competitors must scrutinize the specific claim language to identify potential design-arounds or opportunities for licensing.
- Patent landscape analysis highlights intense innovation, especially in nanotechnology-driven delivery platforms, aligning with China’s biotech expansion.
- Maintaining freedom-to-operate involves continuous monitoring of related patents and possible licensing negotiations.
- Strategic patent drafting and prosecution are critical for patent holders to sustain market dominance and leverage licensing opportunities.
FAQs
1. What types of innovations are typically protected in Chinese pharmaceutical patents like CN102697790?
Chinese pharmaceutical patents protect chemical compounds, formulations, delivery methods, and manufacturing processes, with claims often tailored to specific molecular structures or innovative delivery systems to extend patent life and market exclusivity.
2. How does CN102697790 compare to similar international patents?
While it may have counterparts in other jurisdictions—such as the US or Europe—the scope and claim language are tailored for China’s IP landscape. Cross-jurisdictional rights depend on patent family strategies and filings abroad.
3. Can a competitor develop a similar drug delivery system circumventing CN102697790?
Yes. By modifying the delivery platform or the chemical structure sufficiently to fall outside the scope of the claims, a competitor could avoid infringement, provided the alternative delivers equivalent therapeutic benefits.
4. What is the significance of patent claims in pharmaceutical patent valuation?
Claims define the legal scope of monopoly; broader claims generally increase a patent’s value. They determine enforceability and exclusivity, directly impacting licensing potential and market power.
5. How do Chinese patent laws influence the patent landscape for biotech drugs?
Chinese patent law emphasizes inventive step and novelty. Recent moves aim to align with international standards, fostering innovation while balancing societal access through strict patentability criteria.
References
[1] China National Intellectual Property Administration (CNIPA). "Patent CN102697790." Accessed February 2023.
